Literature DB >> 23774533

Heteromeric dopamine receptor signaling complexes: emerging neurobiology and disease relevance.

Melissa L Perreault1, Ahmed Hasbi, Brian F O'Dowd, Susan R George.   

Abstract

The pharmacological modification of dopamine transmission has long been employed as a therapeutic tool in the treatment of many mental health disorders. However, as many of the pharmacotherapies today are not without significant side effects, or they alleviate only a particular subset of symptoms, the identification of novel therapeutic targets is imperative. In light of these challenges, the recognition that dopamine receptors can form heteromers has significantly expanded the range of physiologically relevant signaling complexes as well as potential drug targets. Furthermore, as the physiology and disease relevance of these receptor heteromers is further understood, their ability to exhibit pharmacological and functional properties distinct from their constituent receptors, or modulate the function of endogenous homomeric receptor complexes, may allow for the development of alternate therapeutic strategies and provide new avenues for drug design. In this review, we describe the emerging neurobiology of the known dopamine receptor heteromers, their physiological relevance in brain, and discuss the potential role of these receptor complexes in neuropsychiatric disease. We highlight their value as targets for future drug development and discuss innovative research strategies designed to selectively target these dopamine receptor heteromers in the search for novel and clinically efficacious pharmacotherapies.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23774533      PMCID: PMC3857642          DOI: 10.1038/npp.2013.148

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  129 in total

1.  Allosteric interactions between GB1 and GB2 subunits are required for optimal GABA(B) receptor function.

Authors:  T Galvez; B Duthey; J Kniazeff; J Blahos; G Rovelli; B Bettler; L Prézeau; J P Pin
Journal:  EMBO J       Date:  2001-05-01       Impact factor: 11.598

2.  Uncoupling the dopamine D1-D2 receptor complex exerts antidepressant-like effects.

Authors:  Lin Pei; Shupeng Li; Min Wang; Mustansir Diwan; Hymie Anisman; Paul J Fletcher; José N Nobrega; Fang Liu
Journal:  Nat Med       Date:  2010-11-28       Impact factor: 53.440

Review 3.  The Akt-GSK-3 signaling cascade in the actions of dopamine.

Authors:  Jean-Martin Beaulieu; Raul R Gainetdinov; Marc G Caron
Journal:  Trends Pharmacol Sci       Date:  2007-03-08       Impact factor: 14.819

Review 4.  Signaling pathways in schizophrenia: emerging targets and therapeutic strategies.

Authors:  Caline S Karam; Jacob S Ballon; Nancy M Bivens; Zachary Freyberg; Ragy R Girgis; José E Lizardi-Ortiz; Sander Markx; Jeffrey A Lieberman; Jonathan A Javitch
Journal:  Trends Pharmacol Sci       Date:  2010-06-25       Impact factor: 14.819

5.  Separation and reformation of cell surface dopamine receptor oligomers visualized in cells.

Authors:  Brian F O'Dowd; Xiaodong Ji; Mohammad Alijaniaram; Tuan Nguyen; Susan R George
Journal:  Eur J Pharmacol       Date:  2011-03-01       Impact factor: 4.432

6.  Dynamic BDNF activity in nucleus accumbens with cocaine use increases self-administration and relapse.

Authors:  Danielle L Graham; Scott Edwards; Ryan K Bachtell; Ralph J DiLeone; Maribel Rios; David W Self
Journal:  Nat Neurosci       Date:  2007-07-08       Impact factor: 24.884

7.  Dopamine D1 and D2 receptor Co-activation generates a novel phospholipase C-mediated calcium signal.

Authors:  Samuel P Lee; Christopher H So; Asim J Rashid; George Varghese; Regina Cheng; A José Lança; Brian F O'Dowd; Susan R George
Journal:  J Biol Chem       Date:  2004-05-24       Impact factor: 5.157

8.  Homodimerization of the beta2-adrenergic receptor as a prerequisite for cell surface targeting.

Authors:  Ali Salahpour; Stéphane Angers; Jean-François Mercier; Monique Lagacé; Stefano Marullo; Michel Bouvier
Journal:  J Biol Chem       Date:  2004-05-20       Impact factor: 5.157

9.  Dopamine D1-D2 receptor heteromer in dual phenotype GABA/glutamate-coexpressing striatal medium spiny neurons: regulation of BDNF, GAD67 and VGLUT1/2.

Authors:  Melissa L Perreault; Theresa Fan; Mohammed Alijaniaram; Brian F O'Dowd; Susan R George
Journal:  PLoS One       Date:  2012-03-12       Impact factor: 3.240

10.  Adenosine A2A-dopamine D2 receptor-receptor heteromerization: qualitative and quantitative assessment by fluorescence and bioluminescence energy transfer.

Authors:  Meritxell Canals; Daniel Marcellino; Francesca Fanelli; Francisco Ciruela; Piero de Benedetti; Steven R Goldberg; Kim Neve; Kjell Fuxe; Luigi F Agnati; Amina S Woods; Sergi Ferré; Carme Lluis; Michel Bouvier; Rafael Franco
Journal:  J Biol Chem       Date:  2003-08-21       Impact factor: 5.157

View more
  54 in total

Review 1.  Emerging role of dopamine in neovascularization of pheochromocytoma and paraganglioma.

Authors:  Thamara E Osinga; Thera P Links; Robin P F Dullaart; Karel Pacak; Anouk N A van der Horst-Schrivers; Michiel N Kerstens; Ido P Kema
Journal:  FASEB J       Date:  2017-03-06       Impact factor: 5.191

Review 2.  GPCRs and Signal Transducers: Interaction Stoichiometry.

Authors:  Vsevolod V Gurevich; Eugenia V Gurevich
Journal:  Trends Pharmacol Sci       Date:  2018-05-05       Impact factor: 14.819

3.  PNA-Based Multivalent Scaffolds Activate the Dopamine D2 Receptor.

Authors:  Andrew V Dix; Jennie L Conroy; Kara M George Rosenker; David R Sibley; Daniel H Appella
Journal:  ACS Med Chem Lett       Date:  2015-03-13       Impact factor: 4.345

Review 4.  Dopamine receptors - IUPHAR Review 13.

Authors:  Jean-Martin Beaulieu; Stefano Espinoza; Raul R Gainetdinov
Journal:  Br J Pharmacol       Date:  2015-01       Impact factor: 8.739

Review 5.  Where Is Dopamine and how do Immune Cells See it?: Dopamine-Mediated Immune Cell Function in Health and Disease.

Authors:  S M Matt; P J Gaskill
Journal:  J Neuroimmune Pharmacol       Date:  2019-05-11       Impact factor: 4.147

6.  Concentration-dependent activation of dopamine receptors differentially modulates GABA release onto orexin neurons.

Authors:  Victoria Linehan; Robert B Trask; Chantalle Briggs; Todd M Rowe; Michiru Hirasawa
Journal:  Eur J Neurosci       Date:  2015-06-26       Impact factor: 3.386

Review 7.  Direct and indirect pathways of basal ganglia: a critical reappraisal.

Authors:  Paolo Calabresi; Barbara Picconi; Alessandro Tozzi; Veronica Ghiglieri; Massimiliano Di Filippo
Journal:  Nat Neurosci       Date:  2014-07-28       Impact factor: 24.884

8.  A peptide targeting an interaction interface disrupts the dopamine D1-D2 receptor heteromer to block signaling and function in vitro and in vivo: effective selective antagonism.

Authors:  Ahmed Hasbi; Melissa L Perreault; Maurice Y F Shen; Lucia Zhang; Ryan To; Theresa Fan; Tuan Nguyen; Xiaodong Ji; Brian F O'Dowd; Susan R George
Journal:  FASEB J       Date:  2014-07-25       Impact factor: 5.191

9.  (-)-Stepholidine is a potent pan-dopamine receptor antagonist of both G protein- and β-arrestin-mediated signaling.

Authors:  Julie A Meade; R Benjamin Free; Nicole R Miller; Lani S Chun; Trevor B Doyle; Amy E Moritz; Jennie L Conroy; Val J Watts; David R Sibley
Journal:  Psychopharmacology (Berl)       Date:  2014-09-18       Impact factor: 4.530

10.  Dopamine D1 or D2 receptor-expressing neurons in the central nervous system.

Authors:  Xiaoyan Wei; Tengfei Ma; Yifeng Cheng; Cathy C Y Huang; Xuehua Wang; Jiayi Lu; Jun Wang
Journal:  Addict Biol       Date:  2017-04-24       Impact factor: 4.280

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.